Page 3 - Presection News Today

Wildfire smoke is associated with worse survival for individuals with non–small cell lung cancer (NSCLC) who are recovering from surgical resection treatment.

Sandip Patel, MD, shares his expert perspectives on novel combination consolidation immunotherapy regimens that are under evaluation in unresectable early-stage NSCLC.

Conclusions from the first interim analysis of overall survival in the IMpower010 trial of adjuvant atezolizumab for non–small cell lung cancer has been met with some pushback.

Expert panelists discuss the characterization of patients with unresectable, early-stage NSCLC and what their standard treatment approach is for this patient population.

Researchers recommend staging laparoscopy for most patients with localized pancreatic ductal adenocarcinoma prior to resection to determine the stage of cancer and metastatic disease.

Ben Levy, MD, reviews the 5-year update and clinical implications of the PACIFIC study which evaluated consolidation immunotherapy in unresectable early-stage NSCLC.

A panel of experts offers their insights into which patients with resectable early-stage NSCLC might be suitable for neoadjuvant versus adjuvant chemoimmunotherapy.

David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC

This_ it and make sure it works for us. this issue — it and make sure it works for us. this issue of— it and make sure it works for us. this issue of regulation, its not easy, is it? this issue of regulation, its not easy. is it?— this issue of regulation, its not easy, is it? its not easy because nobody knows — easy, is it? its not easy because nobody knows how— easy, is it? its not easy because nobody knows how the _ easy, is it? its not easy because i nobody knows how the technology...

Although patients with metastatic nonseminomatous germ-cell tumors who had teratoma in the primary tumor were found to have a higher rate of teratoma in residual non-retroperitoneal disease following chemotherapy, those without teratoma in the primary tumor could have teratoma or active testicular germ-cell tumors in residual disease post-chemotherapy and should be considered for resection.